{"analyses":[{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.86","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0016","paramType":"Hazard Ratio (HR)","paramValue":"0.67","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.63","upperLimit":"20.30","value":"17.91"},{"groupId":"OG001","lowerLimit":"19.55","upperLimit":"30.69","value":"25.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"185"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"The PD-L1-selected subpopulation is defined as patients in the ITT population whose PD-L1 status is IC1/2/3 at the time of randomization.","reportingStatus":"POSTED","timeFrame":"Baseline until death due to any cause (up to approximately 58 months)","title":"OS in Participants With Detectable PD-L1","type":"PRIMARY","unitOfMeasure":"Months"}